Home › Compare › ATNNF vs ABBV
ATNNF yields 1.73% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ATNNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ATNNF + ABBV for your $10,000?
Autoneum Holding AG develops and manufactures acoustic and thermal management solutions for the automotive market. It offers multifunctional and lightweight components and systems for noise and heat protection. The company provides engine and e-motor encapsulations, frunks, outer dashes, hoodliners, engine top covers, engine and body-mounted absorbers, and outer trunk floor insulators; and underbody products, including under floor and under engine shields, wheelhouse outer liners, outer tunnel and floor insulators, battery electromagnetic shields, under battery shields, and heatshields, as well as battery and spare wheel pans. It also offers interior floor products comprising inner dashes, needle punch and tufted carpets, floor insulators and mats, inner wheelhouse and trunk floor insulators, and dampers; and other components, such as ultra-silent for underbody systems, di-light for carpet systems, prime-light and IFP-R2 for inner dashes and floor insulators, hybrid-acoustics PET for conventional insulation, mono-liner for wheelhouse outer liners, and relive-1 under the Autoneum Pure label; and measurement systems, as well as performs simulations and tests. The company has operations in Europe, North America, Asia, South America, the Middle East, and Africa. Autoneum Holding AG was founded in 1901 and is headquartered in Winterthur, Switzerland.
Full ATNNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.